FAM134B isoform 2/RETREG1-2 defines a calnexin-TOLLIP-coupled ER-phagy pathway that restricts Ebola virus glycoprotein and is antagonized by VP40 through macro-autophagy

This study identifies the truncated FAM134B isoform 2 (RETR1-2) as a calnexin- and TOLLIP-dependent ER-phagy receptor that selectively degrades Ebola virus glycoprotein to restrict infection, while revealing a reciprocal arms race where the viral protein VP40 counteracts this defense by triggering RETR1-2's own degradation via macro-autophagy.

The Gist

The Story: A High-Stakes Game of Hide-and-Seek in the Cell's Factory

Imagine your body's cells are bustling factories. Inside these factories, there is a massive, complex workshop called the Endoplasmic Reticulum (ER). This is where the cell builds its most important products, including the "keys" (proteins) it needs to function.

When the Ebola virus invades, it hijacks this factory. It forces the ER to churn out millions of viral "keys" (called Glycoproteins or GP) that the virus needs to infect other cells.

This paper tells the story of a specific security guard in the factory who tries to stop the virus, and how the virus tries to fight back.

---

1. The Security Guard: RETR1-2

The cell has a security system called ER-phagy (which sounds like "eating the ER"). Think of this as a specialized trash disposal unit that eats specific parts of the factory floor to clean up messes.

For a long time, scientists thought the main security guard, a protein called RETR1 (the "Full-Length" version), was the one stopping Ebola. But this paper reveals a twist: The Full-Length guard is actually on vacation.

Instead, it's his younger, shorter sibling, RETR1-2 (an "isoform"), who is doing the heavy lifting.

• The Job: RETR1-2 spots the viral keys (Ebola GP) as soon as they are made.
• The Action: It grabs them and throws them into the cell's "trash compactor" (the lysosome) to be destroyed.
• The Result: Without these keys, the Ebola virus cannot build its infection machine, and the virus is stopped in its tracks.

2. The Secret Team: The "Calnexin-TOLLIP" Squad

How does RETR1-2 know exactly which keys to grab? It doesn't work alone. It needs a special team:

• Calnexin (The Quality Inspector): Imagine Calnexin as a quality control inspector standing on the factory floor. When the virus tries to build its keys, Calnexin notices they look "wrong" or "suspicious." Calnexin tags them and hands them over to RETR1-2.
• TOLLIP (The Delivery Driver): Once RETR1-2 has the viral keys, it needs a driver to take them to the trash compactor. This is TOLLIP.
  • The Surprise: Usually, trash drivers need a "ticket" (a molecule called ubiquitin) to know what to pick up. But in this case, TOLLIP doesn't need a ticket. It grabs the viral keys directly because it recognizes the specific shape of the RETR1-2 team. This is a unique, "ticket-free" delivery system.

3. The Virus Fights Back: VP40

The Ebola virus is smart. It has a weapon called VP40.

• The Counter-Attack: VP40 acts like a saboteur. It sneaks into the factory and specifically targets the security guard, RETR1-2.
• The Sabotage: VP40 grabs RETR1-2 and forces the cell to destroy the guard instead of the virus. It's like the virus kidnapping the security guard and throwing him into the trash compactor.
• The Result: With the guard gone, the viral keys (GP) are no longer destroyed. The virus can now build its infection machine and spread.

4. The Reciprocal Fight (The "Mutual Assured Destruction")

Here is the most interesting part: It's a two-way street.

• While VP40 tries to destroy RETR1-2, RETR1-2 also tries to destroy VP40.
• They are locked in a constant tug-of-war. If the virus produces too much VP40, it wins. If the cell produces enough RETR1-2, it wins.
• However, when they destroy each other, they use a different method than the one used for the viral keys. They don't need the "Quality Inspector" (Calnexin) or the "Delivery Driver" (TOLLIP) for this fight; they just destroy each other directly.

The Big Picture: An Evolutionary Arms Race

This paper describes a microscopic arms race:

1. The Host (You): Develops a specialized security team (RETR1-2 + Calnexin + TOLLIP) to spot and destroy viral parts without needing complex "tickets."
2. The Virus (Ebola): Evolves a weapon (VP40) to specifically target and eliminate that security team.
3. The Host: Retaliates by trying to destroy the weapon.

Why does this matter?
Understanding this specific "ticket-free" trash system gives scientists new ideas for how to fight Ebola. If we can boost the activity of RETR1-2 or TOLLIP, or find a way to stop VP40 from destroying them, we might be able to help the body's natural defenses crush the virus before it spreads.

Summary in One Sentence

The cell uses a special "short" security guard (RETR1-2) and a ticket-free delivery driver (TOLLIP) to spot and trash Ebola virus parts, but the virus fights back by kidnapping and destroying the guard, creating a constant battle for survival inside the cell.

Technical Summary

1. Problem Statement

• Context: Ebola virus (EBOV) is a highly pathogenic filovirus. Its replication critically depends on the synthesis and folding of its envelope glycoprotein (GP) within the Endoplasmic Reticulum (ER).
• Knowledge Gap: While the ER-phagy receptor RETREG1 (also known as FAM134B) was previously identified as a host factor that restricts EBOV replication in vivo, the specific molecular mechanism remained unclear. It was unknown which isoform of RETREG1 is responsible, how the viral GP is recognized, which host adaptors are involved, and how the virus counteracts this defense.
• Specific Question: How does the host cell utilize ER quality control and selective autophagy (ER-phagy) to degrade EBOV-GP, and how does EBOV evade this mechanism?

2. Methodology

The study employed a comprehensive multidisciplinary approach combining molecular biology, cell biology, and virology:

• Cell Models: Utilized HEK293T cells, HeLa cells, and various CRISPR-Cas9 knockout (KO) cell lines (e.g., RETREG1-KO, TOLLIP-KO, CANX-KO, ATG-KO lines) to dissect specific pathway components.
• Viral Systems:
  • Pseudovirions (PVs): HIV-1 particles pseudotyped with EBOV-GP to measure infectivity.
  • trVLPs: Transcription- and replication-competent virus-like particles to recapitulate the full EBOV life cycle.
• Molecular Techniques:
  • Western Blotting & Co-Immunoprecipitation (Co-IP): To assess protein expression levels, degradation, and protein-protein interactions.
  • Mass Spectrometry (IP-MS): Unbiased screening of RETR1-2 interactors to identify host cofactors.
  • Domain Mapping: Construction of deletion mutants (e.g., ΔLIR, ΔTM, ΔC2) to define functional domains.
  • Pharmacological Inhibition: Use of lysosomal inhibitors (Bafilomycin A1, Concanamycin A), autophagy inhibitors (3-MA, LY294002), and proteasome inhibitors (MG132) to determine degradation pathways.
  • Confocal Microscopy: To visualize subcellular localization and colocalization of proteins (e.g., with ER markers like Calreticulin).
  • Cycloheximide Chase Assays: To measure protein half-life and degradation kinetics.

3. Key Contributions

The paper defines a novel, non-canonical ER-phagy pathway and reveals a reciprocal host-virus arms race:

1. Isoform Specificity: Identified RETR1-2 (the truncated isoform of FAM134B) as the specific ER-phagy receptor for EBOV-GP, distinguishing it from the full-length RETR1.
2. Novel Adaptor Mechanism: Discovered that TOLLIP acts as a critical cytosolic adaptor for RETR1-2, functioning independently of ubiquitination via its PI3P-binding C2 domain.
3. Chaperone Dependence: Established that the ER chaperone Calnexin (CANX) is essential for recruiting EBOV-GP to the RETR1-2 complex.
4. Viral Antagonism: Uncovered that the viral protein VP40 specifically targets RETR1-2 for degradation to neutralize the host defense.
5. Reciprocal Degradation: Revealed a bidirectional "arms race" where RETR1-2 degrades VP40, and VP40 degrades RETR1-2, utilizing distinct autophagic mechanisms.

4. Key Results

A. RETR1-2 is the Specific Antiviral Receptor

• Screening: Among various ER-phagy receptors (TEX264, RTN3L, ATL3, etc.), only RETR1-2 significantly reduced EBOV-GP expression (by ~10-fold) and viral infectivity. Full-length RETR1 showed no antiviral activity.
• Specificity: RETR1-2 degraded GPs from multiple ebolavirus species (Sudan, Bundibugyo, etc.) but not Marburg virus.
• Mechanism: RETR1-2 recognizes EBOV-GP via its luminal loop domain (residues 153-89). The C-terminal LIR motif is required for recruiting the autophagy machinery (LC3/GABARAP).

B. The Calnexin–TOLLIP–RETR1-2 Axis

• Pathway Identification: IP-MS identified TOLLIP and Calnexin (CANX) as key interactors.
• Calnexin Role: Co-expression in KO cells showed that RETR1-2-mediated degradation of GP is strictly dependent on CANX, but not on other chaperones like Calreticulin (CALR) or PDIA3.
• TOLLIP Role:
  • TOLLIP binds RETR1-2 via its C2 domain (PI3P-binding).
  • Ubiquitin-Independence: Unlike canonical ER-phagy, this pathway does not require cargo ubiquitination. EBOV-GP mutants lacking ubiquitination sites or the cytoplasmic tail were still degraded by RETR1-2/TOLLIP.
  • Oligomerization: EBOV-GP induces RETR1-2 oligomerization (dependent on the cholesterol-binding residue E118), which is necessary for degradation.

C. Viral Counter-Attack: VP40 Antagonism

• VP40 Targeting: Among all EBOV proteins, only VP40 specifically reduced RETR1-2 protein levels in a dose-dependent manner.
• Mechanism: VP40 interacts with the C-terminal domain (CTD) of RETR1-2, recruiting it to the ER.
• Degradation Pathway: VP40 induces the macro-autophagic degradation of RETR1-2. Crucially, this degradation is independent of TOLLIP and CANX, suggesting a distinct mechanism where the VP40-RETR1-2 complex is recognized as an aberrant assembly.
• Outcome: VP40 restores EBOV-GP expression and viral infectivity by degrading the host receptor.

D. Reciprocal Degradation

• Bidirectional Conflict: RETR1-2 also degrades VP40 via macro-autophagy (independent of TOLLIP/p62).
• Result: This creates a dynamic "arms race" where the host attempts to degrade viral proteins, and the virus attempts to degrade the host receptor.

5. Significance

• Redefining ER-Phagy: The study challenges the dogma that ER-phagy receptors always require ubiquitination for cargo recognition. It demonstrates a ubiquitin-independent pathway mediated by the Calnexin-TOLLIP-RETR1-2 axis.
• Isoform Functionality: It highlights the functional divergence between full-length RETR1 and its truncated isoform RETR1-2, suggesting that alternative splicing creates specialized receptors for specific stressors (like viral infection).
• Therapeutic Implications: Understanding this host-virus conflict identifies potential targets for broad-spectrum antivirals. Enhancing the Calnexin-TOLLIP-RETR1-2 axis or blocking VP40's ability to degrade RETR1-2 could restrict EBOV replication.
• Broader Impact: The findings provide a model for how ER quality control systems are hijacked or adapted during viral infections, offering insights into the evolution of host defense mechanisms against filoviruses.